Only a few, single GF-based formulations have been approved, by US-FDA (Food and Drug Administration) bone morphogenic protein (BMP)-2 and BMP-7 for lumbar spine fusion and bone fracture, platelet derived growth factor in BB isoform (PDGF)-BB for enhancement of granulation tissue formation and keratinocyte growth factor (KGF) for the prevention and treatment of mucositis in cancer patients; and by Japan and China, fibroblast growth factor (FGF)-2; and by Latin America and part of Asia, epidermal growth factor (EGF), all for wound healing [126]. Here, FGF7 is linked to mucositis.